- Home
- XERS vs CRI Comparison
XERS vs CRI Comparison
Compare XERS & CRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- CRI
- Stock Information
- Founded
- XERS 2005
- CRI 1865
- Country
- XERS United States
- CRI United States
- Employees
- XERS N/A
- CRI N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- CRI Apparel
- Sector
- XERS Health Care
- CRI Consumer Discretionary
- Exchange
- XERS Nasdaq
- CRI Nasdaq
- Market Cap
- XERS 1.3B
- CRI 1.0B
- IPO Year
- XERS 2018
- CRI 2003
- Fundamental
- Price
- XERS $7.64
- CRI $32.54
- Analyst Decision
- XERS Strong Buy
- CRI Sell
- Analyst Count
- XERS 7
- CRI 4
- Target Price
- XERS $9.43
- CRI $29.50
- AVG Volume (30 Days)
- XERS 3.0M
- CRI 1.3M
- Earning Date
- XERS 11-06-2025
- CRI 10-27-2025
- Dividend Yield
- XERS N/A
- CRI 3.06%
- EPS Growth
- XERS N/A
- CRI N/A
- EPS
- XERS N/A
- CRI 2.45
- Revenue
- XERS $266,137,000.00
- CRI $2,832,687,000.00
- Revenue This Year
- XERS $43.89
- CRI $1.58
- Revenue Next Year
- XERS $20.40
- CRI N/A
- P/E Ratio
- XERS N/A
- CRI $13.33
- Revenue Growth
- XERS 42.05
- CRI N/A
- 52 Week Low
- XERS $2.82
- CRI $23.38
- 52 Week High
- XERS $10.08
- CRI $58.13
- Technical
- Relative Strength Index (RSI)
- XERS 36.31
- CRI 57.90
- Support Level
- XERS $7.00
- CRI $29.40
- Resistance Level
- XERS $10.08
- CRI $32.66
- Average True Range (ATR)
- XERS 0.53
- CRI 1.93
- MACD
- XERS -0.26
- CRI 0.01
- Stochastic Oscillator
- XERS 23.38
- CRI 63.17
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About CRI Carter's Inc.
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.